Tracer library / [177Lu]Lu-Rituximab

[177Lu]Lu-Rituximab

Also written as [Lu-177]Lu-Rituximab; Lu-177-Rituximab

Radionuclide: Lu-177 t½ 9584.6 min
Modality: Therapy
Production route: —
Stage: Preclinical
Syntheses indexed: 1

Preclinical only, no clinical indication yet

What it is

Compound class: DOTA-conjugated anti-CD20 monoclonal antibody radioimmunoconjugate (rituximab)
Target / mechanism: CD20 antigen on B-cells PMID 41793834
Clinical application: Non-Hodgkin lymphoma (radioimmunotherapy) PMID 28181275
Theranostic pair: —

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
Manual synthesis	—	SPE	—	95%	p-SCN-Bn-DOTA	23256748 2013 Curr Radiopharm The antibodies tetulomab and rituximab were first labeled with p-SCN-Bn-DOTA dissolved in 0.005M HCl.

Need this precursor?We can point you to suppliers for [177Lu]Lu-Rituximab, or handle the enquiry for you.

Get in touch

Notes

Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 2 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 23256748: 'the backbone substituted chelator p-SCN-Bn-DOTA (tetraxetan)'. Stage set/updated at stage 39 from PMID 28181275: 'Pharmacokinetic behavior of the agent, evaluated by biodistribution studies in normal Swiss mice, revealed high blood and liver uptake at the initial time points'.